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Objective: Complete exclusion and depressurization of the aneurysm sac is the prime goal of endovascular repair (EVAR)
of abdominal aortic aneurysms. Thus, any EVAR that results in a type I or III endoleak has been classified as a technical
failure. The current method to detect endoleaks uses intraoperative aortography. However, aortography is limited by its
subjective nature, inability to quantify the significance of the endoleak, and artifacts such as bowel gas that may mimic an
endoleak. In addition, repetitive contrast injection may impair renal function. To increase the efficacy and safety of
intraoperative endoleak detection, a wireless pressure-monitoring system has been developed and tested in the clinical
setting.
Methods: The APEX trial (Acute Pressure Measurement to Confirm Aneurysm Sac EXclusion) is a prospective, multi-
center/international trial sponsored by CardioMEMS to evaluate the safety and efficacy of the EndoSure wireless
pressure sensor for EVAR. The 30  5  1.5-mm sensor contains no battery and is powered externally with
radiofrequency energy. The sensors are extremely stable, operate over the full physiologic range of pressures, and have a
resolution of 1 mmHg. A total of 90 patients were enrolled at 12 sites, 76 of whom were eligible for analysis. The sensor
was implanted via the contralateral femoral artery at the time of EVAR. The sac pulse pressure was measured with both
an angiographic catheter and the sensor after deployment of the main endograft but before the deployment of the
contralateral limb (type I endoleak equivalent). Sac pressure was again measured with the sensor after deployment of the
contralateral limb and completion of the EVAR. Data were collected in a prospective manner.
Results: In all of the eligible patients (n  76), the initial sensor pressure measurement agreed closely with the
angiographic catheter pressure measurement of the type I endoleak equivalent. At the completion of the procedure, there
was agreement between the sensor measurement and angiography regarding the presence or absence of a type I or III
endoleak in 92.1% (n  70) of the measurements. Overall, the sensitivity was 0.94 and the specificity was 0.80 for
detecting type I or III endoleaks. Final pulse pressures decreased significantly compared with baseline measurements.
Conclusions: Implantation of the wireless pressure sensor is safe, and remote aneurysm sac pressure sensing is feasible. It
was a valuable guide in evaluating the completeness of the EVAR procedure. Long-term study will be needed to prove its
efficacy for postoperative surveillance. ( J Vasc Surg 2007;45:236-42.)The primary goal of any abdominal aortic aneurysm
(AAA) treatment is to reduce the pressure in the aneurysm
sac and prevent rupture. Complete exclusion will allow
depressurization of the sac, whereas failure to exclude the
aneurysm from the systemic circulation results in continued
pressurization.1-4 Endoleaks, especially type I and III leaks,
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236lead to continued increases of sac pressure and, therefore,
have been defined as technical failures.4,5 Currently, the
completeness of exclusion or absence of endoleaks is eval-
uated by intraoperative angiography. The presence of con-
tinued perfusion of the sac with contrast probably corre-
lates well with sac pressurization in most cases. However,
the absence of contrast filling of the sac is not always an
accurate predictor of the absence of endoleaks. First, in the
absence of outflow, contrast material does not easily flow
into the sac. Second, imaging the AAA sac is difficult: the
sac is located deep inside the abdomen, and this makes
angiographic imaging challenging, unlike in the carotids or
the lower extremities. To increase the sensitivity for
detecting endoleaks, most (if not all) operators use dig-
ital subtraction angiography, which can lead to false-
positive findings due to artifacts from bowel gas, respira-
tion, and pre-existing contrast inside the sac. Uncertainty
regarding the presence or absence of endoleaks on comple-
tion angiography may lead to multiple contrast injections in
different projections, thus leading to an increased risk of
JOURNAL OF VASCULAR SURGERY
Volume 45, Number 2 Ohki et al 237contrast-induced nephropathy and increased radiation ex-
posure for both the patient and surgeon.
However, measurement of sac pressure gives a physio-
logical assessment of operative success, because it directly
measures the most important end point of endovascular
aneurysm repair (EVAR): reduction in sac pressure.1-4 Pre-
vious studies have used direct sac pressure measurement
with an angiographic catheter. The obvious drawback of
this technique is the interference of the catheter with the
seal formed by the stent graft. Additionally, the catheter
cannot be kept inside the body for a prolonged period of
time.
To improve the outcome of EVAR, a wireless and
batteryless implantable pressure sensor was developed
(EndoSure sensor; CardioMEMS, Inc, Atlanta, Ga). The
sensors are designed to operate over the full physiologic
range of pressures and have a resolution of 1 mm Hg. The
APEX trial (Acute Pressure Measurement to Confirm An-
eurysm Sac EXclusion) was a prospective, multicenter/
international trial to evaluate the safety and efficacy of the
EndoSure sensor for detecting intraoperative type I and III
endoleaks during EVAR with commercially available stent
grafts.
MATERIALS AND METHODS
The objective of this study was to determine whether
intraoperative EndoSure sensor pulse pressure measure-
ments correlate with angiographic findings in terms of the
presence or absence of type I or III endoleaks. Systolic,
diastolic, mean, and pulse pressures in the sac were mea-
sured by using the EndoSure sensor during and at the
completion of stent graft placement. In addition, a nonin-
vasive blood pressure cuff and an arterial line were used to
measure systemic blood pressure.
The primary efficacy variable was the correlation be-
tween the EndoSure sensor and angiography to confirm sac
exclusion during the endovascular stent-graft procedure.
The clinical hypothesis was that a reduction in pulse pres-
sure of 30% or more from the initial EndoSure sensor sac
pulse pressure measurement (baseline; before aneurysm
exclusion) would be associated with a sealed sac, whereas a
less than 30% reduction in pulse pressure would indicate a
type I or III endoleak. Because such endoleaks are infre-
quently encountered during the EVAR procedure, we de-
fined a type I endoleak equivalent. A type I endoleak
equivalent was defined as the endoleak seen after the release
of the stent graft’s main body but before the deployment of
the contralateral limb. Physiologically, this is equivalent to
a large distal type I endoleak. The sac pressure measure-
ment was repeated after the completion of the EVAR (after
all the components were deployed and touch-up balloon-
ing was performed as indicated).
Secondary efficacy parameters of interest were pressure
measured on the day of discharge, procedure evaluation
and procedure difficulties, assessment of the access site at
the discharge evaluation, and detection of a sensor signal at
the 30-day evaluation. Safety parameters analyzed wereadverse events and deaths occurring within the 30-day
evaluation period.
Patients completed the baseline screening require-
ments at the preoperative examination and received a stent
graft and the EndoSure sensor within the following 12
weeks. Various pressures were measured during surgery.
Patients were evaluated at discharge and at the 30-day
follow-up for adverse events. Angiographic and computed
tomographic (CT) images were submitted to a core labo-
ratory (Cleveland Clinic Peripheral Vascular Core Lab,
Cleveland, Ohio) and independently reviewed by a quali-
fied radiologist.
Patient selection. All patients who met the acceptance
criteria for insertion of a bifurcated, modular endovascular
stent graft for the treatment of infrarenal AAAs or aortoiliac
aneurysms according to the instructions for use of the
selected endograft were candidates for implantation of the
EndoSure sensor. The only unique anatomic requirement
for the implantation of the sensor was that CT scanning
should demonstrate that adequate space was available for
the sensor within the aneurysm sac (10 mm after stent-
graft insertion). In one patient, this criterion was not met,
and the sensor was not inserted. The sensor is typically
placed in the largest segment of the aneurysm sac, although
this is not strictly necessary or always achievable.
In addition, the patients needed to agree to comply
with the follow-up requirements of the study. Standard
exclusion criteria for EVAR were specified. In the United
States, only commercially available stent grafts were used.
Food and Drug Administration and local institutional re-
view board approval were obtained before the clinical trial
was initiated, and written informed consent was received in
all cases.
The EndoSure sensor. The sensor has a nitinol basket
surrounding the electronic components (Fig 1). It has no
battery and is powered externally. In vivo testing has shown
that the sensor continues to function over several years and
is extremely stable. It is calibrated during the deployment
procedure and does not require recalibration. The sensor
itself is composed of flexible plates bearing inductor wind-
ings inside a hermetically sealed reference cavity. A change
in the pressure surrounding the EndoSure sensor will
change the position of the plates, thereby changing the
capacitance and resonant frequency of the sensor. The
change in resonant frequency can be monitored by external
electronics (antenna), and this allows measurement of the
pressure in the aneurysm sac. Sensor interrogation results in
a real-time pressure trace of the sac pressure, which is
displayed on an external monitor (Fig 2). The EndoSure
sensor is mounted inside a 14F sheath, which is introduced
over an existing wire. The sensor is attached to a tether
wire, which is used to maintain the position of the sensor
during retrieval of the delivery system. This tether wire and
the super-stiff wire that was used for over-the-wire delivery
exit from the proximal end of the delivery system.
Implantation technique. Although some cases were
performed percutaneously, the vast majority of the cases
were performed via bilateral femoral cutdowns. After the
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ture was performed on the side of the main endograft
insertion, and a guidewire was introduced into the de-
scending aorta. This guidewire was exchanged for a super-
stiff support wire, and the endograft or the delivery sheath
was introduced. To prevent the ipsilateral wire (the side of
the main body insertion) from passing through the nitinol
basket of the EndoSure sensor, the ipsilateral wire was intro-
duced before the EndoSure sensor was deployed (Fig 3). The
same steps were performed in the contralateral femoral
artery, and a super-stiff wire was placed into the thoracic
aorta. The EndoSure sensor delivery sheath was then intro-
duced over this super-stiff wire. Once the EndoSure sensor
was located inside the sac, the outer sheath was withdrawn
over the pusher rod (Fig 3). Care was taken so that the
EndoSure sensor was kept slightly proximal to the desired
target site. Then, the delivery system (including the metal
jacket that was protecting the EndoSure sensor) was re-
trieved from the body, leaving behind only the sensor and
Fig 1. The EndoSure sensor. Top: Schematic cross section of the
sensor. Bottom: Fabricated sensor. The basket surrounding the
sensor has no electrical functionality but acts to keep the sensor
centered within the sac. The sensor is approximately 5 mm wide
and 30 mm long so as to sample a reasonable fraction of the large
volume of the aneurysm sac.the tether wire attached to the sensor (Fig 3). During thisprocess, the sensor delivery system was exchanged over
the tether wire and the super-stiff wire, thereby keeping the
sensor position stable and maintaining wire access to the
aneurysm with the super-stiff wire. Once the sensor delivery
sheath was completely withdrawn from the patient, a pigtail
Fig 2. External monitor and the antenna.
Fig 3. A, The EndoSure sensor delivery sheath with a radiopaque
tip marker (R) is introduced over the stiff wire after wire access has
been obtained for the main body delivery or after the endograft
delivery sheath (D) has been introduced. M, Metal jacket that
contains the EndoSure sensor. B, The sensor delivery sheath and
the metal jacket are retrieved while the sensor (S) position is
maintained with the tether wire. The arrow denotes the ra-
diopaque markers placed at both ends of the EndoSure sensor. C,
Once the sensor delivery sheath has been withdrawn, a pigtail
catheter is introduced over the existing stiff wire, and angiography
is performed for endograft deployment while the sensor (S) is kept
inside the sac. Calibration of the sensor and baseline sac pressure
measurement with both the angiographic catheter and the sensor
are also performed at this time.catheter was introduced over the super-stiff wire. Calibra-
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measurements with both the angiographic catheter and the
sensor were also performed at this time. Systemic blood
pressure measurement was recorded with an arterial line as
well as with the brachial cuff. Angiography was then per-
formed via the pigtail catheter for endograft deployment
while the sensor was kept inside the sac (Fig 3).
The main body of the bifurcated endograft was then
deployed, leaving a large type I endoleak equivalent. At this
time, sac pressure measurements were performed with both
the angiographic catheter and the EndoSure sensor to
measure the type I endoleak equivalent. Then, cannulation
of the contralateral stump was performed with standard
techniques, and the contralateral limb was deployed. The
use of the touch-up balloon was left to the physician’s
discretion. At this point, because the EndoSure sensor was
confined within the sac and isolated from the circulation,
the tether wire was pulled to release the sensor. After all the
necessary steps were accomplished, a completion aorto-
gram was performed, and the presence and type of endoleak
were recorded. In addition, the systemic blood pressure
and the sac pressure with the EndoSure sensor were re-
corded. These pressure measurements were performed be-
fore leaving the procedure suite. Additional pressure mea-
surements were performed at 30 days to confirm sensor
function. Ongoing pressure measurements continue to be
taken at regular patient follow-up intervals (ie, 6 months, 1
year, 2 years, and so on) and will be the subject of future
articles.
RESULTS
After completion of a 15-patient feasibility trial in
which sensor accuracy was confirmed by simultaneously
measuring the pressure wirelessly and through a standard
angiographic catheter that had been left in the aneurysm sac
after stent-graft deployment, 90 patients were enrolled at
12 sites in 4 countries between July 2004 and January
2005. All patients were fully compliant with the inclusion
and exclusion criteria at the screening visit except for one
who did not have adequate space in the aneurysm sac for
implantation of the EndoSure sensor. Before hospital dis-
charge, protocol deviations, typically a missed measure-
ment, prevented analysis of 14 patients, and these patients
were excluded from the per-protocol population. There-
fore, the intention-to-treat population included 90 pa-
tients, and the per-protocol population included 76 pa-
tients. Of the 90 patients enrolled, only 1 died before
hospital discharge. Of the surviving patients, all completed
the 30-day follow-up evaluation, except for one who died
on day 29 before the follow-up visit.
Patient demographics. Of the 76 patients in the per-
protocol population, 86.8% (n 66) were male. The mean
age of the per-protocol population was 72.3 years (range,
56-88 years). The mean weight was 81.6  15.3 kg or
180.2 pounds (33.7 pounds).
Type of stent graft used and basic operative
information. The mean maximum aneurysm diameter in
the per-protocol population was 5.48  1.07 cm (range,3.85-10.1 cm; the single case with a 4-cm AAA was in a
patient who had a saccular aneurysm). The most commonly
used stent grafts in the per-protocol population were the
Zenith (Cook, Indianapolis, Ind) and Excluder (WL Gore,
Flagstaff, Ariz; n  27 for both), which comprised 71% of
the implants. Other stent grafts included 8 AneuRx
(Medtronic, Santa Rosa, Calif) in the United States and 3
Talent (Medtronic) and 11 Apolo (Nano Endoluminal,
Florianopolis, Brazil) at outside the United States sites.
There was no significant difference between intraoperative
endoleak rates among the different types of stent grafts.
The mean estimated blood loss for the intention-to-treat
population was 436  387 mL, and the mean operating
room time was 190  98 minutes. In the per-protocol
population, the mean estimated blood loss was 471  387
mL, and the operative time was 205  87 minutes.
Primary efficacy parameter. In all of the per-protocol
patients, the initial pressure measurement during the type I
endoleak equivalent agreed between the angiographic cath-
eter and the sensor (Fig 4). At the completion of the
procedure, there was final agreement between the Endo-
Sure sensor measurement and angiography for determi-
nation of a type I or III endoleak in 92.1% (n  70; P 
.05) of the patients (Table). At the completion of the
procedure, the pulse pressure decreased significantly
compared with the baseline measurement (Fig 5). Seal-
ing of the sac was associated with a mean decrease in
pulse pressure of 46%.
During the clinical trial, there were several occasions
Fig 4. Correlation of mean sac pressure at the first pressure
reading between EndoSure sensor and the angiographic catheter
positioned in the aneurysm sac.








Endoleak present 4 1 5
Endoleak absent 5 66 71
Total 9 67 76
Specificity, 0.934; sensitivity, 0.800.when real-time pressure sensing during EVAR was used
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cance in terms of pressurization of the sac. Such an
example is shown in Fig 6. Owing to this physiological
evaluation, the AAA was treated effectively without mul-
tiple contrast injections.
There were five instances of disagreement between the
EndoSure sensor and angiography (Table). In four of these
cases, postexclusion measurements showed a less than 30%
reduction in sac pressure, although there was no visible
endoleak on angiography (false positive). Serial pressure
measurements on these patients subsequent to EVAR dem-
onstrated a gradual reduction of pulse pressure within the
aneurysm sac.
In one patient, pulse pressure as measured by the
EndoSure sensor decreased by more than 30% even
though angiography revealed what was interpreted as a
small type I endoleak (false negative). The investigator
did not consider the endoleak significant and chose not
to treat it; at the 30-day follow-up evaluation, there was
no further evidence of the endoleak, and the sac pressure
remained stable.
In 96.6% (n  87) of the entire intention-to-treat
population and 97.3% (n  74) of the per-protocol
population, the sensor signal could be detected at the
30-day evaluation. In one patient, the signal could not
be detected at the 30-day measurement but was present
on subsequent visits. One patient died before discharge,
and one patient died after discharge but before the
30-day evaluation.
Through the 30-day evaluation, 21.1% (n 19) of the
patients experienced 23 anticipated adverse events, and
17.7% (n  16) of the patients experienced 18 other
unanticipated adverse events. Adverse events were classified
as unanticipated if they were not included in the investiga-
tional plan. The most common anticipated adverse events
were arterial occlusion (not related to the sensor), delayed
wound healing, and endoleaks. The most frequent unan-
ticipated adverse events were pain, fever, and hospitaliza-
tion, all of which were probably related to the EVAR
procedure. There were no adverse device events (ie, due to
the sensor). There was also no evidence of device migra-
tion, and sensor performance was not affected by the pres-
Fig 5. Comparison between sac pulse pressure before and after
endovascular aneurysm repair (EVAR). A significant reduction was
seen with EVAR (P  .05).ence of thrombus in the sac.Deaths. Two deaths through the 30-day evaluation
period were reported. Both deaths were classified by the
investigator as nonrelated to the sensor or the implantation
procedure. The first death was an 85-year-old man whose
comorbidities included hypertension and arthritis. This
patient received an AneuRx stent graft in a procedure that
lasted approximately 3 hours. Estimated blood loss was
1000 mL, and the patient received 800 mL of packed red
blood cells. The family informed the site coordinator that
the patient died before the 30-day follow-up visit. The
investigator was told that the cause of death was probably
due to a myocardial infarct.
The second death was a 72-year-old man whose comor-
bidities included a history of myocardial infarction, high
cholesterol, and hypertension. He received a Zenith stent
graft in a procedure that lasted approximately 4.5 hours.
Estimated blood loss was 1600 mL, and he received 1000
mL of packed red blood cells. There were no procedure
difficulties. The patient developed acute pulmonary edema
shortly after leaving the operating room, and the edema
worsened. Cardiopulmonary resuscitation was performed,
but the patient died.
Nonevaluable patients. Of 90 patients who received
the EndoSure sensor during the study, 14 (15.6%) were
classified as nonevaluable and were excluded from the
per-protocol analyses. These patients had protocol devia-
tions mostly due to missing data points, thus leading to
exclusion from the per-protocol analysis. There was a defi-
nite learning curve associated with refining the technique
for insertion of the implants, interrogation of the sensor,
operation of the electronics, and proper completion of the
case report forms. In 12 cases, proper EndoSure sensor
function was confirmed after surgery, and further operator
training resulted in improved compliance with the study
protocol.
DISCUSSION
Effective EVAR requires complete exclusion of the
aortic aneurysm sac. The presence of most type I or III
endoleaks is considered a technical failure and needs to be
identified and addressed at the time of implantation.5 Cur-
rently, the standard tool used for intraoperative endoleak
assessment is angiography. However, angiography has
many shortcomings: it may not be accurate in obese pa-
tients; interpretation can be difficult when artifact exists
(Fig 6); and, most relevantly, there is the inability to assess
sac pressure reduction and thus understand the physiologic
significance of a visible endoleak.
This study was designed to evaluate the clinical useful-
ness of a wireless implantable pressure sensor and the value
of noninvasive sac pressure measurements performed dur-
ing operative insertion of a stent graft. Specifically, it was
our aim to determine whether the EndoSure sensor can aid
in the assessment of sac exclusion during EVAR. Because
true type I or III endoleaks are rarely encountered during
EVAR, endoleak after main graft insertion but before con-
tralateral limb insertion was defined as a type I endoleak
equivalent. Baseline pressure was measured during the type
End
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the end of the case to confirm sac exclusion and pressure
reduction. The accuracy of the EndoSure sensor to diag-
nose the endoleak equivalent proved to be 100%, with no
false-positive or -negative results. In addition, measure-
ment of the sac pressure with simultaneous pressure
readings with an angiographic catheter or sheath showed
excellent correlation between the two values and con-
firmed sensor accuracy. Although anecdotal cases have
been reported with another type of wireless pressure
sensor,6,7 this is the first time the accuracy and feasibility
of a wireless, batteryless sensor has been evaluated in a
large-scale trial.
Using the reduction in sac pressure pulsatility to verify
sac exclusion was a very effective strategy in this patient
population. Overall, the sensitivity was 0.939 and specific-
ity was 0.800 for detecting type I or III endoleaks. There
were five cases of type I or III endoleaks according to
intraoperative angiography. Of these, four were success-
fully detected with the EndoSure sensor (30% decrease in
pulse pressure), and in the remaining case, the sensor
showed a significant decrease in the pressure. In this case,
the endoleak on the angiogram was a small type I endoleak
that showed up on delayed images, and the investigator
considered it too insignificant to warrant treatment. This
endoleak seemed to be due to an irregular neck and later
thrombosed and sealed: a significant pressure decrease was
seen during the follow-up, and there was an absence of
endoleak and sac enlargement on follow-up CT scan. Al-
though this case was classified as a false-negative result per
Fig 6. Completion angiogram following EVAR. A: Pre
space for the Endograft and the EndoSure Sensor. B: Ear
possibly communicating with the inferior mesenteric arte
(E) and the communication with the inferior mesenteric
material. However, the significance and the origin of theprotocol definitions, the clinical outcome would suggestthat the pressure sensor provided more relevant informa-
tion than the angiogram.
During the clinical trial, there were several occasions
when real-time pressure sensing was used to determine the
specific type of endoleak. In one case, an endoleak that was
originally thought to be at the left distal attachment site
(type I) was in fact originating from the right side, thus
altering the course of treatment for this patient. Although
this study was not designed to address this question, it is
possible that in the future the use of the sensor during
EVAR procedures could reduce the volume of contrast
needed to assess the success of stent-graft deployment and
allow more precise determination of the type of endoleak.
Such quality control during EVAR has been proposed by
others using angiographic catheters for pressure measure-
ment.4
As with all new technologies, there was a learning curve
associated with learning the appropriate methods of using
the sensor, delivery system, and external electronics. This
resulted in less-than-optimal sensor positioning or inade-
quate calibration procedures during some of the initial
implantations. This was especially true during the early
phase of the trial, when we were using the first-generation
system. The manufacturer has since made significant im-
provements both in the delivery system and in the external
electronics, and the system has become much more user
friendly. Overall, the system was easy to use, and the
optimal techniques for sensor implantation and pressure
interrogation could be mastered after the first few proce-
dures. This was proven by the reasonable operating room
ative angiogram shows an infra-renal AAA with enough
ase of the completion angiogram shows an Endoleak (E)
. C: Latter phase angiogram clearly shows the Endoleak
ry. The entire aneurysm sac was opacified with contrast
oleak were not clear.-oper
ly ph
ry (I)
artetime and estimated blood loss, both of which were in line
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estimate that approximately 10 minutes of procedural time
was added to the existing EVAR procedures. In the vast
majority of the cases, the interrogation of the sensor was
performed within 30 seconds.
Patients will be followed up for 5 years, with evaluation
at 6 and 12 months and then annually. If a patient requires
enhanced follow-up, as defined in the commercially mar-
keted AAA stent-graft labeling, or at the physician’s discre-
tion, more frequent interrogation of the EndoSure sensor
may occur. In addition, long-term data will provide infor-
mation to evaluate the value of the sensor for postoperative
follow-up surveillance. Such data will be the focus of a
different study and will be reported in a separate article.
CONCLUSIONS
The implantation of the EndoSure wireless pressure
was straightforward and safe. The EndoSure sensor mea-
sured sac pressure accurately, and pressure sensing was able
to detect the type I endoleak equivalent as well as true type
I and III endoleaks during EVAR with excellent accuracy.
Pressure sensing also confirmed effective exclusion of the
sac, and, therefore, intrasac pressure sensing may be a useful
adjunct to intraoperative angiography.
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